Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Sanofi (SNY) Stock Price
Press coverage about Sanofi (NYSE:SNY) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sanofi earned a news impact score of 0.10 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.0953084980054 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Sanofi $SNY Shares Sold by HL Financial Services LLC https://t.co/2EwfWl7ibe (4-traders.com)
- Sanofi’s Zika Standoff: Bad Medicine? – Seeking Alpha (seekingalpha.com)
- Brandes Investment Partners, Lp Sold A Little More Sanofi American Depositary Shar (SNY) Stock In The Last Quarter – Modern Readers (modernreaders.com)
- UPDATE 1-Mexico watchdog finds big pharma faces no competition on some drugs (feeds.reuters.com)
- Sanofi (SNY) Sues to Defend its Patent Rights on Lantus – StreetInsider.com (streetinsider.com)
Sanofi (NYSE SNY) traded up 0.38% on Monday, reaching $47.73. The company had a trading volume of 451,270 shares. The stock has a 50 day moving average of $47.95 and a 200 day moving average of $46.27. The firm has a market capitalization of $119.87 billion, a PE ratio of 11.28 and a beta of 0.88. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24.
Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. The firm had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. Sanofi’s quarterly revenue was down 2.3% on a year-over-year basis. On average, analysts anticipate that Sanofi will post $3.26 EPS for the current year.
A number of research firms have recently commented on SNY. BidaskClub upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Cowen and Company reiterated a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Argus raised their price target on Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Friday, June 2nd. Finally, Berenberg Bank downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $63.75.
TRADEMARK VIOLATION WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-sanofi-sny-stock-price/1487947.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.